Singapore markets closed

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.4000-0.0200 (-1.41%)
At close: 04:00PM EDT
1.4000 0.00 (0.00%)
After hours: 05:10PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.4200
Open1.4055
Bid1.4000 x 100
Ask1.4200 x 400
Day's range1.3907 - 1.4200
52-week range0.9900 - 1.8900
Volume42,108
Avg. volume151,754
Market cap75.581M
Beta (5Y monthly)0.63
PE ratio (TTM)3.18
EPS (TTM)0.4400
Earnings date08 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 28, 2024, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 227,500 restricted stock unit awards (RSUs) to new employees under the Spero Therapeutics, I

  • Zacks

    Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?

    Denali Therapeutics (DNLI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

  • GlobeNewswire

    Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

    CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the H.C. Wainwright 2nd Annual BioConnect Investor